Download Free Ecab Clinical Hepatology E Book Book in PDF and EPUB Free Download. You can read online Ecab Clinical Hepatology E Book and write the review.

ECAB Clinical Hepatology - E-Book
ECAB Non-alcoholic Fatty Liver Disease - E-Book
ECAB Recent Advances in Hepatology - E-Book
Get the authoritative, up-to-date information you need on liver disease from the 7th Edition of the most trusted reference worldwide. Covering both basic science and recent clinical developments, this revised edition by Drs. Arun J. Sanyal, Thomas D. Boyer, Norah A. Terrault, and Keith D. Lindor, provides an in-depth, comprehensive look at the pathophysiology, diagnostic, and treatment information related to the liver. More than 1,100 figures and tables, many new and in full color, highlight completely updated content throughout. Expert, international authorship and comprehensive, easy-to-access information makes this edition the gold standard in the field of hepatology. Includes new information on the rapid changes in treatment paradigms for acute liver failure, the latest treatments for primary biliary cholangitis, full coverage of the gut microbiome and its role in liver disease, the newest developments in drug-induced liver injury, and changes in hepatitis C virus treatment and hot-button concerns about access to care. New summary boxes at the end of each chapter and a newly streamlined table of contents make it easier to find and understand the information you’re looking for. Hundreds of brand-new illustrations clearly present key aspects of liver disease.
Non-alcoholic fatty liver disease is a common cause of chronic liver disease, and its incidence is rising worldwide. Understanding its pathogenesis, biochemical parameters, histological grading and staging, and its management is a vital issue in today’s clinical practice. It appears to be linked directly to the growing epidemic of obesity in adults as well as in children. Thus, in a sense, NAFLD is a self-inflicted liver disease, much like alcoholic liver disease. The exact causes responsible for the development of NAFLD have not been established yet. However, some researchers consider that cluster of disorders that increases the risk of developing heart disease, diabetes, and stroke may be the factor behind development of NAFLD. Most patients with NAFLD have no symptoms or signs of liver disease at the time of diagnosis. In these patients, abnormal liver function tests are often discovered incidentally. Non-alcoholic steatohepatitis (NASH) is that stage of the spectrum that involves fat accumulation (steatosis), inflammation (hepatitis), and scarring (fibrosis) in the liver. Those who have fatty liver or hepatic steatosis with non-specific inflammation as fatty liver with non-specific inflammation generally have a benign longterm prognosis, whereas those who have NASH can progress to cirrhosis. NASH-related cirrhosis may have similar prognosis as cirrhosis from other causes. Hepatocellular carcinoma (HCC) is part of the spectrum of NAFLD, and screening for HCC seems reasonable in patients who have NASH-related cirrhosis. No established treatment is available for NAFLD. Some empiric treatment strategies have been suggested. Presumably, weight loss through exercise and diet modification along with insulinsensitizing agents will help reverse fatty infiltration of the liver. Its incidence is reportedly on the rise the world over as well as in India. Realizing its significance, there is now greater understanding of its etiology, pathogenesis, and management. The efforts of Elsevier have been directed toward addressing these aspects. Elsevier has thus pooled its existing resources with those of the internationally acclaimed Gastroenterologists of India who have chosen to share their rich clinical knowledge, experience, and expertize to serve the practitioners and patient community.
Zakim and Boyer’s Hepatology—the defining work in hepatology—presents comprehensive coverage of both basic science and clinically relevant developments so you can provide the best possible patient care. Drs. Thomas Boyer, Michael Manns, and Arun Sanyal have reorganized and updated the contents of this trusted global reference to reflect today’s more clinical approach to hepatology. They bring you up to date on hot topics including HIV Co-Infection Drug Toxicity, Hepatocellular Carcinoma (HCC), and much more. This new streamlined edition is now a single volume making it easier to find the treatment information you need. Effectively treat all liver diseases currently seen in clinical practice with authoritative guidance from leading international authorities. Reinforce your foundation in basic science with the concise Pathophysiology of Therapeutic Targets section. See clear presentations of liver disease through hundreds of detailed, color illustrations. Explore topics further with up-to-date references that direct you to the significant literature. Stay current on new developments in the field through five new chapters on Pathogenesis Liver Injury in HBV, HCV; HCC; Imaging and Non-Invasive DX Liver Disease CT, US, Fibroscan, MRI; HIV Co-Infection Drug Toxicity; and HBC, HCV in Non-Liver Transplant Patients, plus comprehensive updates throughout. Apply best practices with reorganized and updated content that reflects today’s need for a more clinical approach to hepatology.
ECAB Cholestatic Liver Disease - E-Book
Clinical Hepatology – Principles and Practice of Hepatobiliary Diseases provides clear and comprehensive coverage of the etiology, mechanisms of disease, diagnosis, and practical management of the entire spectrum of liver and biliary disorders. It also affords an excellent, evidence-based review of the rapidly expanding field of hepatobiliary diseases.
ECAB Recent Advances in Hepatology